Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States

Rubin, J.L.; McGarry, Lisa; Strutton, David; Klugman, Keith P.; Pelton, Stephen I.; Gilmore, Kristen E.; Weinstein, Milton C.

doi:10.1016/j.vaccine.2010.09.049

Cited by 89 publications

(87 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Details of the Markov model as applied to the United States are published elsewhere. 58 The analysis takes both payer and the societal perspectives, and the primary outcome for each country is the incremental cost per life year and QALY gained for PCV10 and PCV13 compared to no vaccination and PCV13 compared to PCV10. Future costs and outcomes were discounted at 3% per annum.…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Roberts

Lee

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Keywords: herd effect, incremental cost-effectiveness ratio (ICER), Markov transition-state model, pneumococcal disease, 13-valent pneumococcal conjugate vaccine (PCV13), 10-valent pneumococcal conjugate vaccine (PCV10)Pneumococcal disease causes large morbidity, mortality and health care utilization and medical and non-medical costs, which can all be reduced by effective infant universal routine immunization programs with pneumococcal conjugate vaccines (PCV). We evaluated the clinical and economic benefits of such programs with either 10-or 13-valent PCVs in Malaysia and Hong Kong by using an age-stratified Markov cohort model with many country-specific inputs. The incremental cost per quality-adjusted life year (QALY) was calculated to compare PCV10 or PCV13 against no vaccination and PCV13 against PCV10 over a 10-year birth cohort's vaccination. Both payer and societal perspectives were used. PCV13 had better public health and economic outcomes than a PCV10 program across all scenarios considered. For example, in the base case scenario in Malaysia, PCV13 would reduce more cases of IPD (C2,296), pneumonia (C705,281), and acute otitis media (C376,967) and save more lives (C6,122) than PCV10. Similarly, in Hong Kong, PCV13 would reduce more cases of IPD cases (C529), pneumonia (C172,185), and acute otitis media (C37,727) and save more lives (C2,688) than PCV10. During the same time horizon, PCV13 would gain over 74,000 and 21,600 additional QALYs than PCV10 in Malaysia and Hong Kong, respectively. PCV13 would be cost saving when compared against similar program with PCV10, under both payer and societal perspective in both countries. PCV13 remained a better choice over PCV10 in multiple sensitivity, scenario, and probabilistic analyses. PCV13s broader serotype coverage in its formulation and herd effect compared against PCV10 were important drivers of differences in outcomes.

show abstract

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Roberts

Lee

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…The most important of these limitations is that many of the 23 serotypes included in the vaccine are poorly immunogenic in infants and children under 2 years of age, which is the age group with the highest incidence of both local and invasive pneumococcal infections. This is especially true for the pneumococcal serotypes 6A, 6B, 14, 19A, 19F, and 23F, which most commonly cause drug-resistant disease in the pediatric population (41,98,99,103). Because polysaccharide antigens are T lymphocyte independent, they do not induce immunologic memory and fail to prime for an anamnestic or booster response with subsequent reexposure.…”

Section: Currently Licensed Vaccinesmentioning

confidence: 99%

Pediatric Invasive Pneumococcal Disease in the United States in the Era of Pneumococcal Conjugate Vaccines

2012

View full text Add to dashboard Cite

SUMMARY Invasive infections caused by Streptococcus pneumoniae continue to be a major cause of morbidity and mortality worldwide, especially in children under 5 years of age. In the United States, 90% of invasive pneumococcal infections in children are caused by 13 serotypes of S. pneumoniae . The licensure (in 2000) and subsequent widespread use of a heptavalent pneumococcal conjugate vaccine (PCV7) have had a significant impact on decreasing the incidence of serious invasive pneumococcal disease (IPD) in all age groups, especially in children under 2 years of age. However, the emergence of replacement non-PCV7 serotypes, especially serotype 19A, has resulted in an increase in the incidence of serious and invasive infections. In 2010, a 13-valent PCV was licensed in the United States. However, the impact that this vaccine will have on IPD remains to be seen. The objectives of this review are to discuss the epidemiology of serious and invasive pneumococcal infections in the United States in the PCV era and to review some of the pneumococcal vaccines that are in development.

show abstract

“…Rubin and colleagues 54 have modeled the impact of infant vaccination in the US with PCV13 vs. PCV7 on pneumococcal disease incidence and mortality as well as the incremental benefit of a serotype catch-up program and their model predicted that PCV13 would be more effective than PCV7 at preventing IPD and would also result in cost savings. Zimmerman and coworkers at the University of Pittsburgh modeled the impact of PCV13 in adults and predicted that use of PCV13 would be highly cost-effective in 50 y olds when compared with current US PPV23 recommendations.…”

mentioning

confidence: 99%

13-valent pneumococcal conjugate vaccine (PCV13)

Jefferies

Macdonald²,

Faust³

et al. 2011

Human Vaccines

View full text Add to dashboard Cite

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States

Cited by 89 publications

References 34 publications

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Pediatric Invasive Pneumococcal Disease in the United States in the Era of Pneumococcal Conjugate Vaccines

13-valent pneumococcal conjugate vaccine (PCV13)

Contact Info

Product

Resources

About